“Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth.” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions (INBS). “In addition to our strong revenue performance, during the quarter we also made significant progress on the regulatory pathway in seeking U.S. FDA 510(k) clearance and continued scaling our operations globally with system upgrades and localization.” The Company expects to report fiscal fourth quarter 2025 revenue increases of approximately 16% sequentially and year-over-year, reflecting continued demand for its higher-margin cartridge sales and steady account growth. Preliminary results indicate sequential revenue growth over both the fiscal third and second quarters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions Submits Key FDA Information
- Intelligent Bio Solutions announces submission of its AI response to U.S. FDA
- Intelligent Bio secures major drug testing tender with transport operator
- Intelligent Bio Solutions Raises $3.8M Through Warrant Deals
- Intelligent Bio Solutions enters agreements to raise $3.8M in gross proceeds